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 Introduction 
 Retinal Anatomy 
A typical feature of the vertebral eye is its invert structure. Light has to pass different layers 
until it reaches the light sensitive layer of the eye, called retina. The retina is a 0.5 mm thin 
layer, which represents a part of the central nervous system. It consists of three distinct layers, 
which house six major cell types including photoreceptors, bipolar cells, horizontal cells, 
amacrine cells and ganglion cells. Müller glia, are the only non-neural retinal cell type which 
provide metabolic and homeostatic support [1], [2]. There are two types of photoreceptors, 
rods and cones. Their cell bodies form the outer nuclear layer (ONL) and are embedded in the 
retinal pigment epithelium (RPE). Retinal pigment epithelium cells are involved in the 
regeneration of the visual pigment and they are responsible for digestion of light-detecting 
compartments of photoreceptors, called outer segments (Figure 1) [2]. The inner nuclear layer 
houses the cell bodies of bipolar, horizontal and amacrine cells. The latter two form synapses 
with the neighboured cells [3]. Rods and cones are able to convert light energy to membrane 
potential change, a process called phototransduction which results in neurotransmitter release 
at the synapse [1]. Rods account for 95% of the photoreceptors in the human retina. They 
enable dim light vision, whereas cones mediate colour and daylight vision. Rods and cones 
are composed of an inner and outer segment (Figure 2). Outer segments contain different 
proteins and pigments essential for phototransduction [4]. By contrast, inner segments contain 
many mitochondria to meet the high energy requirements of photoreceptors. 
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Figure 2: Rod (l.) and cone (r.) photoreceptor structure. Both cell types can be divided into an 
outer and inner segment and the synaptic ending. Inner and outer segment are coupled by the 
connecting cilium.  
 
 
 Retinitis pigmentosa 
Retinitis pigmentosa (RP) is the most common genetic cause for blindness worldwide and 
affects one in 3.000 - 8.000 people [5]. The disease can be syndromic or non-syndromic with 
X-chromosomal, autosomal dominant or autosomal recessive inheritance [6]. In the case of 
syndromic RP, in addition to blindness the patients present with additional symptoms in other 
tissues or organs [6]. One prominent example for syndromic RP is the Usher syndrome, as 
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described in detail in the section below. So far, mutations in over 60 different genes have been 
associated with RP [7]. Most of them affect genes expressed in photoreceptors and retinal 
pigment epithelium, making it very challenging to establish common treatment strategies [6]. 
The phenotypic variability of RP depends on many factors including the type of inheritance, 
genetic background of the patient, or mutation type [8], [9]. The degeneration of photoreceptor 
cells starts in the mid-fringe of the retina and expands towards the macula lutea and fovea, 
leading to progressive visual loss [5]. As a consequence, the outer nuclear layer gets thinner 
and eventually gets almost entirely depleted [6], [10]. Patients become aware of the pathology 
when they notice symptoms like night blindness, progressive constriction of visual fields and 
peripheral vision loss. Symptoms get worse over time and end in tunnel vision or complete 
blindness [7]. This is primarily caused by the degeneration of rods followed by the secondary 
loss of cones [2], [11]. In later stages, when cones become affected, patients will also suffer 
from bad colour and daylight vision, as well as from photophobia, which is an intolerance to 
light exposure [6], [9]. Finally, loss of central vision will manifest [2]. In patient´s fundus, bone-
spicule shaped pigments in the mid-periphery and shrinking of retinal vessels can be observed. 
In the end stage of RP, no or very weak signal is present in patients´ electroretinograms (Figure 
3) [6]. RP equivalents also exist in other mammals, such as dogs where the clinical picture is  
led progressive retinal atrophy (PRA) [9] 
 
Figure 3: End stage fundus of patients carrying Retinitis pigmentosa. Black dots represent 




 Degenerative retinal disorders in mammals 
During the last decades a variety of naturally occurring gene mutations causing retinal 
disorders with a stationary or progressive clinical picture could be identified in mammals [12], 
[13]. Around 29 different mutations are described in literature to cause degenerative or 
developmental retinal disorders in dogs (Figure 4) [13]. The Briard carries a naturally occurring  
mutation located in the RPE65 gene, which belongs to the group of stationary retinal disorders. 
This mutation leads to severe visual impairment similar to what can be observed in humans 
suffering from Leber congenital amaurosis (LCA) [14]. RPE65 is known to be involved in 
retinoid metabolism. Mutations in RPE65 lead to an accumulation of all-trans-retinyl esters, 
very low levels of the visual pigment rhodopsin, a dysfunction of rod photoreceptors as well as 
inclusions in the RPE in mice [15]–[18]. Acland et al. could restore vision in RPE65-/- deficient 
dogs by a subretinal injection of adeno-associated virus serotype 2 (AAV2/2) expressing a 
correct copy of the diseases gene. On the basis of their findings it became possible to develop 
the first gene therapy drug, called LuxturnaTM , for patients suffering from biallelic mutations in 
RPE65 [19]. Based on the clinical phenotype observed in affected dogs, progressive retinal 
atrophies (PRAs) can be denoted as the canine equivalent of retinitis pigmentosa (RP) where 
mutations in the related genes lead to photoreceptor decay over time [9]. PRAs are 
characterized by initial loss of rod function followed by the degeneration of cones. Typically, 
the first clinical signs are night blindness, followed by vision impairment under daylight 
conditions. PRAs can be subdivided into early- and late-onset forms. The Papillon suffers from 
PRA caused by a naturally occurring CNGB1 mutation. The clinical phenotype in these dogs 
is similar to that in humans suffering from RP. Consequently, this dog is an appropriate large 
animal model for autosomal recessive retinitis pigmentosa [9], [13]. Another breed also 
became important in science, namely the Miniature longhaired dachshund, which hosts a 
RPGRIP1 gene mutation. Due to his small size and the clinical observations found in affected 
individuals, this dog model helped to develop treatment strategies for human retinal disorders 
like LCA, RP and cone-rod degeneration (CRD) [20]–[22]. Because of the similarities between 
dog and man, with regard to the clinical features of RP, the size of the eye as well as the 
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photoreceptor density, dogs are very attractive animal models for RP and other retinal 
disorders [9], [23]. Inherited retinal dystrophies have also been described in other animals and 
often resemble the human clinical phenotypes. One example is the homozygous Appaloosa 
horse which carries a naturally occurring mutation in TRIPM1 gene (also known as melastatin). 
The TRIPM-1 protein is expressed in ON bipolar cells of the retina and in the skin and plays 
an essential role for bipolar cell signalling and melanocyte function. Mutations in this gene lead 
to a downregulation or rather absence of a functional protein, a phenotype which is called 
complete congenital stationary night blindness (cCSNB) [24], [25]. Affected horses typically 
show impaired night vision from birth [26]. Inherited retinal dystrophies have also been found 
in other small animals, such as cats [27]. Cases of progressive retinal atrophy as well as rod-
cone dysplasia are described in breeds like the Abyssinian, Somali, Persian, or Bengal cat 
[27]–[30]. The breed of the Abyssinian cat harbors a naturally occuring single-base deletion in 
the CRX gene, which results in a premature stop codon and early onset rod cone dysplasia 
(rdy) [31], [32]. First clicial signs like nystagmus or mydriasis occur early in life and dysplasia 
affects rods and cones equally. Retinal dysplasia is caused by improper development of 
photoreceptor cells [27], [28], [33]. Another example of inherited retinal diseases in Abyssinian 
cats is the progressive rod-cone degeneration (rdAc) attributable to mutations in the CEP290 
gene, a gene causing RP or LCA in humans [27], [28]. In these animals starting from an age 
of 1.5 to 2 years, rods start to degenerate followed by a loss of cones [34], [35]. The tapetal 
layer starts to change its colour and reflectivity accompanied by vascular sustenance in more 
peripheral areas of the fudus. In later stages retinal thinning and hypereflectivity can be 
observed, finally ending in complete loss of visual function at the age of 3 to 4 years [28]. In 
addition to the rdAc, other cat models for inherited retinal dystrophies also exist, such as the 
Bengal cat showing an early-onset autosomal recessive blindness (Figure 5 and 6), or the 






Figure 4: Categorization of canine retinal disorders. Figure taken from Mellersh CS. 2014.  
 
 
Figure 5 (l.) and 6 (r.): Color fundus photographs and photomicrographs of Bengal cats 
suffering from PRA. Area centralis from an obligate carrier Bengal kitten at 8 weeks of age (l.). 
Funduscopic signs usually become evident between 8 to 20 weeks of age and comprise a 
generalized increase in granularity and subsequent reflectivity of the tapetum lucidum, among 
mild retinal vascular attentuation (A,B) and I, J Bengal kitten fundus at 62 weeks of age (r.). 
Complete retinal degeneration, apparent as tapetal hyperreflectivity and absence of retinal 
arterioles or venules can be seen. Figure taken from Ofri et al. 2015. 
 
 
 Usher syndrome 
The Usher syndrome (USH) is an autosomal recessive disease characterized by deafness, 
vision loss due to RP, and occasional vestibular dysfunction [37]. With a prevalence in the 
range of approximately 1: 6.000, USH is the most common cause for hereditary deaf-blindness 
worldwide [38], [39]. Depending on the onset and severeness of the disease, there are three 
different types of the Usher syndrome. Type 1 (USH1) is the most severe form and 
characterized by congenital deafness, vestibular dysfunction and early-onset RP [2]. Mutations 
in six different genes were found in USH1 patients. MyosinVIIA (USH1B), Harmonin (USH1C), 
Cadherin-23 (USH1D), Protocadherin-15 (USH1F), Sans (USH1G) and Cib2 [40]–[45]. 
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Patients with USH2 suffer from moderate to severe hearing loss, normal vestibular function 
and RP starting in the second decade of life. USH2 is caused by mutations in the genes 
Usherin, NBC-3, VLGR1b or Whirlin [2], [46]–[48]. Usher syndrome type 3 (USH3) is primarily 
caused by mutations in USH3A (also known as CLRN1), a gene encoding for the protein 
CLRN-1. Patients suffering from USH3 present with the most variable clinical phenotype which 
includes progressive RP, hearing loss and vestibular dysfunction [2]. Another gene associated 
with USH3 is HARS (histidyl-tRNA synthetase) [49]–[51].  
USH3 accounts for 1-6% of all USH cases worldwide. However, its prevalence is highly 
enriched in some populations, such as the Ashkenazi Jews and the Finnish population (up to 
40% of USH3 cases) [52], [53]. Most of the USH genes encode for large scaffold proteins 
responsible for the maintenance of the complex architecture of photoreceptor and hair cells, 
where they form multiprotein complexes [2]. Furthermore, these proteins are involved in cell 
adhesion, intracellular trafficking and G-protein- or Ca2+-mediated signalling [2]. Hearing 
impairment can be efficiently treated by the help of cochlear implants, however, there is no 
curative therapy for the vision loss in USH patients [54]. One important factor hampering the 
development of treatment strategies for this disease is the lack of appropriate animal models 
(e.g. rodents) mimicking the visual phenotype of human patients. One explanation could be 
the missing photoreceptor calyceal process in rodents and/or other unknown mechanisms 
compensating the lack of functional USH proteins in these animals [55], [56]. As there is no 
therapy available for patients suffering from any of the USH subtypes there is an unmet need 
for development of new translational approaches. 
 
 Pre-mRNA splicing 
In eukaryotic cells the transcription of DNA into pre-mRNA (messenger RNA) is followed by 
three important steps of RNA processing: pre-mRNA splicing, 5´-end capping and 3´-
processing. These parts are required before mature mRNA can be exported to the cytoplasm 
as functional mRNA. Splicing of mRNA requires several critical elements, like the 5´ (donor) 
and 3´ (acceptor) splice sites, the consensus sequences, a branch site, a polypyrimidine 
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sequence and splicing enhancers. These elements are recognized by small nuclear 
ribonucleoproteins (snRNPs) (U1, U2, U4, U5 and U6) and other protein splicing factors, which 
are part of the so called spliceosome [57], [58]. In eukaryotic cells the pre-mRNA contains 
protein-coding regions (exons) and non-coding regions referred to as introns. During the 
splicing process the spliceosome reassembles on every intron and thereby catalyses a trans-
esterification reaction, which leads to the removal of the intron and ligation of exons. This 
results in a mature mRNA which can be translated into functional proteins. To be identified by 
the splice machinery, the exon-intron boundaries contain specific recognition sequences called 
splice sites. These include a donor site (5´end of the intron), a branch site (near the 3' end of 
the intron) and an acceptor site (3' end of the intron). 
 
 Splice mutations 
Approximately 15% of all disease-causing mutations are predicted to affect mRNA splicing 
[59]–[61]. As described in the previous section, an accurate splicing process requires the 
spliceosome and numerous of other splicing factors. Regularly, pre-mRNA splicing occurs with 
high fidelity, nevertheless pre-mRNA mis-splicing can happen in presence of disease-causing 
mutations [62]. Typically, splicing mutations are localized at the canonical donor and acceptor 
splice sites, which define the boundaries between exons and introns. However, aberrant 
splicing can also occur due to mutations in deep intronic parts of a pre-mRNA. This altered 
splicing process can happen via diverse mechanisms [63].  
One of the most common mechanisms is the generation of novel exons in intronic regions. 
Due to diverse screening methods, e.g. Next generation sequencing (NGS), it became possible 
to identify deep intronic mutations in genes involved in the development of retinal dystrophies 
[63]–[68]. Because of the large number of deep intronic mutations identified within the last 





  CLRN1 
CLRN1 is located on chromosome 3 and spans about 46 kb. It encodes a four-transmembrane 
protein (CLRN-1) that belongs to the large family of tetraspanins and claudin (Figure 7) [50], 
[65], [69]. These tetraspanins form large interaction complexes with other neighbouring 
membrane proteins and serve various functions such as cell to cell adhesion, transmission of 
signals and scaffolding function [69], [70]. The exact molecular function of CLRN-1 is largely 
unknown. However, the protein is expressed in the inner segments and ribbon synapses of 
photoreceptor cells, as well as in hair cells of the inner ear [53], [69].  
CLRN1 gene can be expressed as different splice variants. The major splice variant contains 
exon 1 to 4 [51]. Nevertheless, the function of these splice variants is unclear, as some may 
underlie nonsense-mediated mRNA decay (NMD), because of premature stop codons, 
whereas others may be translated into functional proteins [39]. The mutation this work is 
dealing with, is a deep-intronic c.254-649T>G CLRN1 mutation found in the Saudi Arabian 
population and is located between exon 0b and exon 1. The point mutation causes a new 
aberrant exon in intron 0b (230bp), which generates a novel donor splice site leading to a 
frame-shift and a premature stop codon (Figure 8). This results in either a shortened protein 
or an unstable transcript due to NMD. This finally is expected to result in severe changes or 
complete loss of CLRN1 function [65]. This mutation is not the only mutation identified in 
CLRN1 gene during the last decades as shown in the table below. 
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Figure 7: CLRN-1 protein structure. A four transmembrane protein located in the inner 
segments and synapses of photoreceptor cells. CLRN-1 belongs to the large family of 
tetraspanins and claudin. 
 
Table 1: Mutations identified in USH3A. 
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Figure 8: Scheme of the CLRN1 gene encompassing exons 0 – 2. 
Lower panel, enlarged version of the gene region with deep intronic c.254-649T>G mutation, 
which generates an aberrant exon in intron 0b. Figure taken from Panagiotopoulos et al. 2020. 
 
 
 Therapy of USH3 
Effective therapy of USH3 is rather challenging for several reasons. One of them is the 
incomplete or missing knowledge of the expression and function of this gene. In addition, for 
unknown reasons CLRN1 KO mice do not develop a retinal phenotype [56]. The absence of 
faithful disease models hinders the development of novel gene therapies [75]. Moreover, 
CLRN1 gene encodes a high number of different splice isoforms and thus encodes several 
transcripts, whose function is poorly understood [2], [39]. Gene delivery via recombinant 
adeno-associated viruses (rAAV) is the gold standard in gene therapy. Unfortunately, rAAVs 
have a limited packaging capacity of around 4.7kb or less. As a consequence only a single 
splice isoform can be delivered at once. Considering all these obstacles, there is an unmet 
need for developing strategies for the treatment of USH3 patients. The advantages of AONs 
and CRISPR-Cas9 gene editing are that both approaches do not depend on gene size or the 
presence of a single splice isoform. 
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 CRISPR-Cas9 
The CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats) technology is 
an important technique to target, edit, modify and regulate any DNA sequence [76], [77]. 
CRISPR-Cas9 technology is based on a naturally occurring form of adaptive immune system 
which is found in many archaea and bacterial genomes [76], [78]. CRISPR-Cas9 was first 
described in Streptococcus, where numerous short direct repeats interspaced with short 
sequences were found in the genome. These antisense-RNAs derived from plasmids and 
viruses of past cell invasions [79]–[81]. This led to the assumption that these sequences could 
have a role in DNA repair or in gene regulation [82], [83]. Three different Cas-systems have 
been described so far, which differ in their molecular mechanisms to recognize and cleave 
nucleic acids [84], [85]. For CRISPR to be used in biotechnological applications, two 
components are required: a guide RNA (gRNA) and the CRISPR-associated endonuclease 
(Cas-endonuclease). The Cas9-endonuclease can e.g. be used to precisely cut out an intronic 
region containing the disease-causing mutation by introducing a double-strand break in this 
region [76], [86]. The other component, called gRNA recruits the Cas9-endonuclease to its 
target locus on DNA. The gRNA spans approximately 20 nucleotides and contains two 
important components: the trans-activating RNA (tacrRNA) at the 5’ prime end that binds the 
Cas9-endonuclease and the CRISPR-RNA (crRNA) at the 3’ prime end called protospacer that 
binds at the DNA target site. Both components are joined by a linker sequence [76]. Three 
nucleotides 3’ to the protospacer the protospacer adjacent motif (PAM) is located, consisting 
of a NGG sequence that is crucial to initiate the hybridization between crRNA and the DNA 
target. As bacterial genomes do not contain such a PAM sequence, the endogenous bacterial 
DNA cannot be targeted by the CRISPR-Cas9 system [87]–[90]. After cleavage of the double 
strand the latter can be reassembled by non-homologous-end-joining (NHEJ) or by homology-
directed-repair (HDR). Cas9-endonuclease, derived from Streptococcus pyogenes bacteria, 
consists of two nuclease domains, the HNH domain to cleave DNA strand complementary to 
the crRNA and the RuvC-like domain, which cleaves the complementary strand [91], [92].              
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This CRISPR-Cas9 gene editing technology, was already approved for first clinical trials 
designed to treat a deep intronic CEP290 gene mutation, causing Leber congenital amaurosis 
in humans [93]. 
 
 Antisense-Oligonucleotides 
Antisense Oligonucleotides (AONs) are RNA-derived molecules consisting of 18 to 30 
nucleotides [94], [95]. Commonly, they are used for the treatment of splice mutations or 
downregulation of gene expression. To become active, AONs have to pass molecular barriers 
like the cytoplasm or nucleoplasm [95]. After internalization they bind on pre-mRNA level 
through Watson-Crick base pairing. The alteration of splicing events via AONs can happen by 
several mechanisms, e.g. by inhibition of mRNA maturation, blocking of translation, RNase-H-
mediated degradation or masking the splice factor recognition site [94], [96]–[98]. The stability 
and binding efficiency of AONs to the target mRNA, strongly depends on their chemistry as 
unmodified nucleic acids are prone to nuclease degradation. Moreover, the plasma protein 
binding capacity of unmodified AONs is very low, accelerating the elimination by the kidney 
[95], [97]. To improve the binding efficacy, tissue uptake, target affinity, nuclease avoidance, 
toxicity and half-life of AONs, some chemical modifications can be done. In the last few years, 
different generations of AONs were developed. For the studies presented in this work, AONs 
with a phosphothioate backbone were used, which are called phosphorothioate 
oligonucleotides (PTOs). They belong to first generation AONs, which contain a sulfur atom in 
the phoshodiester bond [99]. This modification should preserve the AONs against nuclease 
degradation, increase their solubility and improve the ability to bind the pre-mRNA [100]. Two 
other groups are the so-called phosphorodiamidate morpholino oligonucleotides (PMOs), 
which contain a ribose sugar or  2´-O-(2-Methoxyethyl)-oligoribonucleotides (2´-MOEs) [94]. 
Due to their small size, the easy way of design and the potential to apply them as naked 
molecules in cell culture as well as in vivo, AONs represent an attractive strategy for treatment 
of genetic disorders [101]. Furthermore, they are low in production costs and are expected to 
be uniformly distributed within the different cell types of the retina upon delivery [101]. 
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Nevertheless, this approach has some important drawbacks, such as the requirement of 
constant supplementation throughout a patient´s lifetime, as well as the dose-dependent 
toxicity [97]. Additionally, they can induce some adverse effects, such as coagulation or 
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Mutations in CLRN1 cause Usher syndrome type III (USH3A), a disease characterized by 
progressive hearing impairment, retinitis pigmentosa and vestibular dysfunction. Due to the 
lack of appropriate disease models, no efficient therapy for retinitis pigmentosa in USH patients 
exists so far. In addition, given the yet undefined functional role and expression of the different 
CLRN1 splice isoforms in the retina, non-causative therapies like gene supplementation are 
unsuitable at this stage. Here, we focused on the recently identified deep intronic c.254-
649T>G CLRN1 splicing mutation and aimed to establish two causative treatment approaches: 
CRISPR-Cas9-mediated excision of the mutated intronic region and antisense oligonucleotide 
(AON)-mediated correction of mRNA splicing. The therapeutic potential of these approaches 
was validated in different cell types transiently or stably expressing CLRN1 minigenes. Both 
approaches led to substantial correction of the splice defect. Surprisingly, however, no 
synergistic effect was detected when combining both methods. Finally, the injection of naked 
AONs into mice expressing the mutant CLRN1 minigene in the retina also led to a significant 
splice rescue. We propose that both, AONs and CRISPR-Cas9, are suitable strategies to 












Usher syndrome is an autosomal recessive genetic disease characterized by deafness, vision 
loss due to retinitis pigmentosa (RP), and occasional vestibular dysfunction. In Usher 
syndrome type 3 (USH3A), these symptoms occur in a progressive and variable manner (1). 
USH3A is commonly associated with mutations in CLRN1, a gene encoding the four 
transmembrane domain protein Clarin-1 of largely unknown function. In the retina, the protein 
is suggested to be localized in the inner segments and ribbon synapses of photoreceptors, 
however, recent data also suggest expression in Müller glia cells (2, 3). This gene encodes 
many different splice isoforms, whose function is also poorly understood (4). CLRN1 mutations 
have an estimated prevalence of 1:100,000 individuals worldwide, however, USH3 is the major 
USH subtype in the Ashkenazi Jewish and the Finnish population (5, 6). We have recently 
identified a novel deep intronic CLRN1 founder mutation (c.254-649T>G) in the Saudi Arabian 
population (7). This splicing mutation generates an aberrant exon, which leads to a frameshift 
and a premature stop codon. 
A substantial portion of all disease-causing mutations (>15 %) are predicted to affect mRNA 
splicing (8-10). Classical splicing mutations are localized at the canonical splice donor and 
acceptor sites defining the exon-intron boundaries. However, splicing mutations can also occur 
in deep intronic regions causing aberrant splicing via diverse mechanisms (11). Next 
generation sequencing (NGS) has made it possible to identify disease-causing deep intronic 
mutations in different genes associated with retinal dystrophies (7, 12-16). As the number of 
studies identifying deep intronic mutations in known or unknown genes increases, there is an 
unmet need for developing appropriate treatment strategies for this type of mutations.  
Effective therapy of RP in USH patients is rather challenging for several reasons. First, many 
USH genes have a large (>4 kb) coding sequence or have a high number of splice isoforms 
encoding several protein-coding transcripts, whose function is hitherto poorly characterized 
(1). Currently, the recombinant adeno-associated virus (rAAV)-mediated gene delivery is the 
gold standard in gene therapy. However, due to the limited packaging capacity of rAAVs (≤4.7 
kb), usually only a single splice isoform may be delivered at a time. Second, the commonly   
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used USH mouse models only reflect the hearing loss phenotype of human patients but not 
the neurodegenerative symptoms of retinitis pigmentosa. This lack of a faithful disease model 
hinders the development and testing of novel gene therapies aimed at the restoration of retinal 
structure and function (17). Given these obstacles, the development of alternative approaches 
for retinal gene therapy in USH patients is indispensable. For the treatment of intronic splicing 
mutations, causative approaches such as CRISPR-Cas9 or antisense oligonucleotides (AONs) 
appear very attractive as they do not depend on gene size or the presence of a single (major) 
splice isoform. 
Herein, we set out to establish CRISPR-Cas9- and AON-based approaches to correct the 
splicing defect of the CLRN1 c.254-649T>G mutation. We show that both approaches can 
substantially rescue the aberrant splicing in transfected or transduced cell lines. Finally, using 
AONs we obtained a significant rescue of mRNA splicing in the mouse retina expressing the 
mutant CLRN1 minigene. These results offer a promising basis for advanced preclinical studies 




Editing of the CLRN1 locus using CRISPR-Cas9 
The c.254-649T>G CLRN1 mutation is located in intron 0b and generates a novel splice donor 
site (SDS), which results in the inclusion of an aberrant exon in the mature mRNA (Fig. 1A). 
To test the CRISPR-Cas9 efficiency for editing the CLRN1 locus, we designed four single guide 
RNAs (sgRNAs, g1-g4) targeting regions flanking the mutation (Fig. 1B). To assess the 
efficiency for the two combinations, we transfected HEK293 cells with the plasmid expressing 
the Streptococcus pyogenes Cas9 and one of the two sgRNA pairs (g1 + g3 or g2 + g4, Fig. 
1C). Both sgRNA combinations result in the excision of the DNA fragment in the native locus 
where the mutation is located. Compared to the g2 + g4 combination, which yielded rather low 
gene editing efficiency (4.36 %  0.2 %), the g1 + g3 combination led to reasonably higher 
values under these conditions (21.22 %  0.62 %) (Fig. 1D). Sanger sequencing of the PCR 
band amplified from the modified CLRN1 locus revealed no substantial background in the 
electropherogram, as it would be expected in case of frequent insertions or deletions in the 
target region (Suppl. Fig. 1A, B).  
Upon transfection, the transgene DNA is typically not taken up by all cells in the culture. To be 
able to calculate the actual editing efficiency of the native CLRN1 locus in HEK293 cells more 
accurately, we transfected HEK293 cells with a SpCas9-T2A-EGFP cassette containing the g1 
+ g3 combination (Fig. 1E) and sorted the GFP positive (GFP+) cells using fluorescence-
activated cell sorting (FACS) (Suppl. Fig. 1C). Indeed, gene editing efficiency in GFP+ cells 
was somewhat higher (25.9 %  0.41 %, Fig 1F) compared to their unsorted counterparts.  
Taken together, this CRISPR-Cas9 approach showed reasonable gene editing efficiency for 
the excision of the c.254-649T>G mutation from the native CLRN1 locus in HEK293 cells. 
 
Correction of CLRN1 mRNA splicing using AONs 
To test the potential of the AONs for correction of aberrant splicing caused by the c.254-
649T>G mutation, we designed five AONs (A1-A5) binding to different regions of the CLRN1 
transcript (Fig. 2A). The AONs were designed to either cover multiple exonic or intronic  
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splicing enhancer motifs or the created donor splice site (Suppl. Table 1). As we could not 
get access to patients’ cells natively expressing the CLRN1 mutation, we co-transfected 
HEK293 cells with AONs (250 nM each) and the wild type or mutant CLRN1 minigenes 
encompassing exons 0b to 1b (Fig. 2B) (7). The RT-PCR from these cells revealed that only 
A2 could lead to a substantial splicing rescue resulting in 62.61 %  2.05 % of correctly spliced 
transcript (Fig. 2C) as measured by densitometric analysis of PCR band intensities. We did 
not investigate the protein expression from these minigenes as they do not encode for any 
native protein product. Due to the large size of the introns in the CLRN1 gene, any annotated 
transcript of this gene encoding a native protein would exceed the capacity of standard 
expression vectors. 
In an attempt to further optimize the efficiency of A2, we tested three additional AONs by 
slightly changing their length or binding position (A2-A2.3, Suppl. Table 1). Among the modified 
versions tested, only A2.2 showed a trending but non-significant improvement in splicing 
rescue efficiency (64.92 %  1.36 %) compared to A2 (Fig. 2D). We also detected two 
additional bands migrating between the bands which represent the correctly or aberrantly 
spliced CLRN1 (Suppl. Fig.1D). These bands were also occasionally observed in cells 
expressing wild type or mutant CLRN1 minigenes in the absence of AONs. Sequencing 
revealed that the lower one of the two bands results from the usage of an alternative splice 
donor site present in the native CLRN1 transcript. The upper band represents a hybrid 
composed of the regularly spliced and the aberrantly spliced transcript. (Suppl. Fig.1E, F). 
These hybrids can occur during the PCR cycling conditions due to the fact that their single 
stranded components are largely built of complementary sequences (18). 
To confirm the effects of the AON treatment on CLRN1 mRNA splicing via another method, we 
carried out qRT-PCR using a primer combination that can specifically amplify the aberrantly 
spliced CLRN1 transcripts and compared it to a primer combination capable of detecting both, 
the correctly and the aberrantly spliced variant. Quantification of the results revealed that the 
expression profile and the ratio of these two qRT-PCR products is very similar between cells 
expressing wild type and AON-treated c.254-649T>G CLRN1 minigenes, but clearly differs 
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from the cells expressing the mutant CLRN1 minigene alone (0.023 %  0.006 % for wt, 0.071 
%  0.015 % for mutant treated with A2.2 and 0.634 %  0.036 % for mutant expressed alone, 
Suppl. Fig. 2A). Furthermore, we assessed a potential dose-dependence of AONs for CLRN1 
splicing correction. Using AON concentrations ranging between 50 - 250 nM, no apparent 
differences in splicing correction could be detected suggesting that A2.2 can act with high 
efficiency even at lower concentrations (Suppl. Fig 2B). 
To test whether AON-based splicing correction might be cell type dependent, we performed 
similar experiments in two additional cell lines i.e. in mouse embryonic fibroblasts (MEFs) and 
in 661W cells, which are immortalized derivatives of murine cone photoreceptors (19). In both 
cell types, AON treatment led to a robust splicing correction although at lower efficiency than 
in HEK293 cells (27.30 %  4.03 % in MEF vs. 39.65 %  0.43 % in 661W cells, respectively) 
(Suppl. Fig. 2C-D). Of note, AON treatment also led to an increase in the expression of 
additional bands, which are only weakly present in cells expressing the wild type CLRN1 
minigene. Analogous to the results obtained from HEK293 cells, one of these bands originates 
from the usage of an alternative splice donor site in the aberrant exon and corresponds to one 
of the annotated, non-protein-coding CLRN1 splice isoforms (ENS000000485607.1). Other 
bands could be identified as hybrids composed of different combinations of correctly spliced, 
aberrantly spliced and alternatively spliced products (Suppl. Fig. 1D-F). 
Finally, we also addressed potential off-targets of AON treatment using RNA-seq of HEK293 
cells co-transfected with the mutant CLRN1 minigene and A2.2. Cells expressing the mutant 
CLRN1 minigene in the absence of AONs served as control. Overall, the correlation of the 
expression levels was high (R2 ~ 0.79) with a slight decrease of basal expression levels in 
AON treated cells. Importantly, among the most changed transcripts (log2 fold change > 2) 
there was no enrichment for transcripts located on or near in silico predicted A2.2 binding sites 
(see Methods for details) (Suppl. Fig. 2E, F). However, we cannot exclude that some off-targets 
might be detectable under conditions which more accurately resemble the native situation, e.g. 
the retina of the patients. When co-expressing the CLRN1 mutant minigene with A2.2, we 
detected four annotated CLRN1 splice isoforms (Suppl. Fig. 2E). By contrast, in HEK293 cells 
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expressing the mutant minigene alone, we detected two of these isoforms, one of which was 
only weakly expressed in the A2.2 treated cells. These results further support the effectiveness 
of the A2.2 treatment on the correction of the mutant CLRN1 mRNA splicing. 
In conclusion, the use of AONs, particularly A2.2, achieved a substantial correction of aberrant 
splicing caused by the c.254-649T>G mutation. AONs therefore provide another possible 
strategy, in addition to the CRISPR-Cas9 approach, for treating USH3A patients carrying this 
mutation. 
 
Combination of CRISPR-Cas9 and AONs in cells stably expressing the CLRN1 minigene 
As CRISPR-Cas9 and AONs act on different levels, i.e. the genomic DNA and the pre-mRNA 
level, respectively, one would expect that combining these technologies would increase the 
splicing rescue efficiency. To test for a potential synergism of the two approaches, we 
generated HEK293 cell lines stably expressing the wild type or the mutant CLRN1 minigene, 
which was randomly integrated into the host genome (Fig. 3A). In this setting, the CLRN1-
specific Cas9/sgRNA complex can target both, the native and the transgenic CLRN1 locus. 
Transfected HEK293 cells transiently expressing CLRN1 minigenes were not used for this 
experiment because transfected plasmid DNA differs from native chromatin in the target cells. 
As the efficiency of CRISPR-Cas9 gene editing is known to depend on epigenetic factors, we 
decided to use cells stably expressing the CLRN1 transgene.  
Surprisingly, stable HEK293 cells co-transfected with the SpCas9- and sgRNAs-containing 
plasmid together with A2.2 resulted in a decreased enzymatic activity of SpCas9. This 
combination yielded significantly lower levels of cut DNA as opposed to cells expressing the 
SpCas9/sgRNA cassette alone or the SpCas9/sgRNA cassette in combination with a control 
AON targeting the rhodopsin locus (Fig. 3B). These results suggest that AONs inhibit the 
enzymatic activity of SpCas9, potentially by binding to the CLRN1 locus at the genomic level. 
Since the binding position of the CLRN1 sgRNAs and A2.2 do not overlap, this inhibition cannot 
be explained by a direct competitive effect of the AON and the sgRNAs, but rather by steric 
hindrance of the SpCas9 enzyme preventing it from binding or cutting the DNA. In line with the 
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results obtained for the genomic level, a subsequent RT-PCR analysis from the same cells 
revealed no apparent synergistic effects of the combinatory approach on the CLRN1 transcript 
(Fig. 3C). Notably, when the SpCas9/sgRNA cassette was expressed alone, the splicing 
correction efficiency (45.92 %  1.24 %) was substantially higher than the DNA cutting 
efficiency (26.8 %  3.22 %), suggesting that the actual gene editing efficiency is higher than 
the values measured by the densitometric analysis of the PCR bands from the genomic DNA.  
Collectively, we show that the combination of CRISPR-Cas9 and AONs has no synergistic 
effect on the correction of the splicing defect caused by the c.254-649T>G mutation, and 
provide the first evidence that AONs might act as locus-specific SpCas9 inhibitors. 
 
CRISPR-Cas9 gene editing in transfected ARPE-19 and transduced human RPE cells 
It is well established that the efficiency of CRISPR-Cas9-mediated gene editing can be cell 
type dependent (20). In this regard, targeting cells which express CLRN1 endogenously would 
be more therapeutically relevant. We therefore tested two different retinal pigment epithelium 
(RPE)-derived cell lines for CLRN1 expression, i.e. ARPE-19 (21) and human retinal pigment 
epithelial (hRPE) cells provided by the LMU Eye Hospital Munich, Germany. Both cell lines 
expressed CLRN1 at similar levels (Fig. 4A) suggesting that this gene might also be expressed 
in native RPE cells in the retina. We first transfected the SpCas9-T2A-EGFP construct in 
ARPE-19 cells and performed FAC-sorting of the GFP positive cells (Suppl. Fig. 3A). After 
analyzing the CLRN1 locus, we obtained a gene editing efficiency comparable to transfected 
or sorted HEK293 cells (19.05 %  0.77 %, Fig. 4B, C). Analogous to the results obtained from 
HEK293 cells shown in Suppl. Fig. 1A, B, sequencing of these bands revealed no obvious 
background signal in the electropherograms (Suppl. Fig. 3B, C).   
To approximate a therapeutically applicable approach, we employed rAAVs (rAAV7m8) as 
gene therapy vectors. Due to their limited genome packaging capacity, the SpCas9 and the 
sgRNAs would have to be co-delivered in two separate rAAV-vectors for in vivo applications. 
We therefore assessed whether our CRISPR-Cas9 approach could perform with similar 
effectiveness in a CLRN1-expressing cell line following dual rAAV co-transduction (Fig. 4D). 
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As the co-transduction efficiency of ARPE-19 cells with two titer-matched rAAVs expressing 
the SpCas9 or the sgRNA cassette was very low (data not shown), we conducted the same 
experiment with hRPE cells. Upon transduction we could detect the CLRN1 bands expected 
to occur after SpCas9-mediated editing of the corresponding locus. Quantification of CLRN1 
editing revealed that this process was more efficient than in HEK293 and in transfected ARPE-
19 cells (29.26 %  2.06 %, Fig. 4E, F). These results show that the endogenous CLRN1 locus 
can be efficiently edited via CRISPR-Cas9, when delivered using a dual rAAV approach. In the 
corresponding electropherograms no background signal was observed (Suppl. Fig. 3D, E). 
 
Quantification and off target-analysis of CRISPR-Cas9-mediated gene editing using NGS 
So far, the efficiency of the CRISPR-Cas9 gene editing was calculated via the densitometric 
analyses of the bands obtained from the genomic DNA of respective cell lines. As this semi-
quantitative approach might not reliably reflect the actual gene editing efficiency, we carried 
out targeted next generation sequencing (NGS) of the PCR products amplified from the 
genomic DNA of two FAC-sorted cell lines transiently expressing the SpCas9-T2A-
EGFP/sgRNA complex, i.e. HEK293 and ARPE-19 cells. The gene editing efficiency for both 
cell lines was substantially higher compared to the semi-quantitative densitometric calculations 
(84.3 % for HEK293 cells and 63.9 % for ARPE-19 cells) (Suppl. Fig. 4A-C). The molecular 
explanation for this discrepancy remains unclear, however, it suggests that the gene editing 
efficiency calculation requires elaborate analyses to be determined more accurately, e.g. by 
single cell sequencing, usage of unique molecular identifiers or by PCR-free methods. 
Moreover, the NGS analysis revealed that in both cell types for the vast majority of cases the 
sequence between the sgRNA target sites was removed as expected (44 – 47 %, Suppl. Fig. 
4D). In this context, we also identified some edited sequences with lower frequencies, which 
contained additional small insertions or deletions at the cut site. However, in all of these cases 
the potential mutation-containing sequence was successfully removed from the intron. From 
this it can be concluded that irrespective of the cell type the majority of sgRNA cutting events 
results the desired DNA modification.   
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It is also conceivable that our CRISPR-Cas9 approach might cause off-targets at the genome 
level. To address this issue, we performed whole exome sequencing (WES) using DNA from 
FAC-sorted HEK293 cells transfected with the SpCas9-T2A-EGFP/sgRNA complex. 
Importantly, no off-targets were detected under these conditions (Suppl. Fig. 4E). Using this 
approach, we could also confirm the deletion of the region flanking the c.254-649T>G mutation 
caused by SpCas9 cleavage (Suppl. Fig 4F). We cannot exclude that off-targets might occur 
in other non-coding (regulatory) regions which cannot be covered by this strategy. This 
requires a whole genome sequencing approach, which is out of scope of this study, but could 
be conducted in appropriate cell lines in a more advanced preclinical setting. 
 
AONs for splicing correction in the retina 
The evaluation of the CRISPR-Cas9 gene editing is more challenging in vivo and would require 
the generation of humanized CLRN1 mouse models. Delivering the CLRN1 minigene via 
rAAVs in vivo would not reflect the conditions required for CRISPR-Cas9 genomic CLRN1 
editing as the rAAV genome resides in the nucleus as an episomal state. However, as AONs 
act at the transcript level, we tested whether the AON-approach would result in correction of 
the splice defect caused by the c.254-649T>G CLRN1 mutation in vivo. For this purpose, we 
used rAAV-mediated gene delivery to express the wild type or mutant human CLRN1 
minigenes in the mouse retina. To ensure correct localization, the CLRN1 minigene was 
expressed under the murine rhodopsin promoter (Fig. 5A). The rAAVs were subretinally 
injected into wildtype C57BL/6J mice alone or co-delivered with A2.2 (Fig. 5B). Four weeks 
after co-delivery, we extracted RNA from the injected retinas and analyzed the mRNA splicing 
of the CLRN1 minigene via RT-PCR. Importantly, when comparing wild type and mutant 
CLRN1 minigene-born transcript in absence of A2.2, we could confirm the splice defect of the 
c.254-649T>G mutation (Fig. 5C). In line with the in vitro experiments, the presence of the 
additional two bands above the regularly spliced CLRN1 was detected for wild type CLRN1 in 
the retina. Co-delivery of A2.2 with the mutant CLRN1 minigene resulted in a significantly 
28  
increased percentage of correctly spliced CLRN1, when compared to the mutant CLRN1 
minigene alone (29.73 %  2.62 % vs. 13.48 %  0.59 %) (Fig. 5D).  
Taken together, we could confirm the mRNA splicing defect of the c.254-649T>G CLRN1 
mutation under a close-to-native setting and show a significant splicing rescue upon co-





Fig. 1 CRISPR-Cas9-mediated CLRN1 editing. A, Upper panel, True to scale representation 
of the CLRN1 gene encompassing exons 0 – 2. gDNA, genomic DNA. Lower panel, The c.254-
649T>G mutation generates an aberrant exon in intron 0b. B, Binding positions of CLRN1 
sgRNAs (g1 – g4) and primers used for amplification of genomic DNA via PCR displayed in D 
and F. C, SpCas9 expression cassette used for the transfection of the cells shown in D. gx and 
gy, single guide RNA combinations (g1 + g3 or g2 + g4). mCMV, minimal CMV promoter. D, 
Upper panel, PCR amplifying the endogenous wild type CLRN1 locus from genomic DNA 
originating from HEK293 cells transiently expressing the SpCas9 with two combinations of 
sgRNAs as indicated. Lower panel, Semi-quantitative densitometric analysis of the DNA 
editing efficiency for the single combinations and untreated (untrd) cells. E, SpCas9-cassette 
used for the transfection of the cells shown in F. F, PCR amplifying the endogenous wild type 
SpCas9 with the g1 + g3 combination. Lower panel, Semi-quantitative densitometric analysis 
of the results shown in the upper panel.  
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Fig. 2 AON-mediated correction of CLRN1 mRNA splicing. A, Binding positions of CLRN1 
AONs (A1 – A5) used for initial screening. Primers used for RT-PCR in C and D are shown as 
arrows. B, Wild type (wt, left) and mutant (mut, right) CLRN1 minigene expression cassettes 
used for the transfection of the cells shown in C and D. C, RT-PCR from HEK293 cells 
transiently expressing the CLRN1 minigene in combination with the single AONs as indicated. 
The corresponding semi-quantitative densitometric analysis is displayed below. D, RT-PCR 
from HEK293 cells transiently expressing wt or mut CLRN1 minigenes in combination with 
different modified versions of A2 (cf. Suppl. Table 1). n.s., not significant. Statistical analysis 
was performed with a one-way ANOVA and Bonferroni’s post-hoc test, *, p ≤ 0.05; **, p ≤ 0,01; 
***, p ≤ 0.001, n = 3. 
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Fig. 3 Combination of AONs and CRISPR-Cas9 in a stable cell line expressing the CLRN1 
minigene. A, wt or mut CLRN1 DNA cassettes used for the generation of the stable HEK293 
cell lines. LTR, long terminal repeat. CMV, cytomegalovirus promoter. pA, polyadenylation 
signal. EF1α, human elongation factor 1 alpha promoter. PuroR, pyromycine resistance gene. 
B, Left panel, PCR from genomic DNA isolated from wt or mutant stable cell lines. The mutant 
cell lines were (co)-transfected with the SpCas9 and sgRNAs containing expression cassette 
and AONs as indicated. AON_ctrl, control AON targeting the rhodopsin (RHO) locus. Right 
panel, semi-quantitative analysis of the PCR band intensities for the three relevant 
combinations shown left. C, Left panel, RT-PCR from the same cells and the same 
combinations as shown in B. Right panel, semi-quantitative analysis of the PCR band 
intensities for the four relevant combinations shown left. Statistical analysis was done with a 
one-way ANOVA and Bonferroni’s post-hoc test, *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001, n = 3. 
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Fig. 4 CRISPR-Cas9-mediated CLRN1 gene editing in transfected ARPE-19 and rAAV-
transduced human RPE cells. A, CLRN1 expression in ARPE-19 and hRPE cells. ΔCT, cycle 
threshold of the CLRN1 expression normalized to beta actin (ACTB). B, PCR of genomic DNA 
isolated from transfected and FAC-sorted ARPE-19 cells. untrd, untreated. C, Densitometric 
analysis of the PCR band intensities shown in B. D, rAAV expression cassette used for 
transduction of hRPE cells. ITR, inverted terminal repeats. E, PCR from genomic DNA isolated 
from transduced hRPE cells one week post-transduction. F, Densitometric analysis of the PCR 





Fig. 5 AON-mediated CLRN1 c.254-649T>G splice rescue in injected retinas. A, wt and 
mut CLRN1 minigene containing rAAV cassettes used for subretinal injections. ITR, inverted 
terminal repeats. mRho, mouse rhodopsin promoter. B, rAAVs in presence or absence of 
naked A2.2 were subretinally injected to wild type C57BL/6J mice. C, RT-PCR from retinas of 
injected mice four weeks post-injection. Two retinas from two different mice were pooled for 
each RT-PCR experiment. Rho expression served as a control. C, Semi-quantitative analysis 
of the PCR band intensities for the single combinations as indicated. Statistical analysis was 







In this study, we evaluate for the first time the potential of CRISPR-Cas9 and AONs as single 
or as combinatory approaches to rescue the splice defect caused by a deep intronic c.254-
649T>G CLRN1 mutation. Both approaches were tested in different human cell lines and 
yielded reasonable splice rescue efficiency. A similar CRISPR-Cas9 approach has been used 
in the past for treatment of deep intronic splicing mutations found in the CEP290 gene causing 
Leber congenital amaurosis (LCA) (22). AONs have also been utilized in the past for treatment 
of splicing mutations in several genes associated with retinal disorders, e.g. LCA, Usher 
syndrome type II or Stargardt disease (23-25). Moreover, both, CRISPR-Cas9 and AONs, have 
been FDA-approved for first clinical trials to treat LCA patients carrying the most common deep 
intronic variant in CEP290, i.e. c.2991+1655A>G (26, 27). This outlines the great potential of 
these technologies for future gene therapies. Here, we provide promising results which could 
represent initial steps towards the first clinical trial for USH3A patients using one of these 
technologies. 
AONs can be delivered intravitreally (or subretinally) as naked molecules expected to distribute 
evenly across the retina and to be taken up by the different retinal cell types. AONs are also 
conveniently produced, which circumvents the elaborate and costly process of rAAV 
production. However, AON-based treatment requires a continuous administration (typically 
every few months) via subretinal or intravitreal injection. This increases the risk of injection-
mediated comorbidities and decreases the patients’ compliance. In contrast, CRISPR-Cas9-
based approaches typically require only a single treatment. The most widely used and best 
characterized Cas9 subtype is SpCas9, derived from Streptococcus pyogenes. SpCas9 can 
be efficiently expressed in all retinal cells utilizing rAAV vectors carrying e.g. the ubiquitous 
minimal CMV promoter (22). Due to the payload limit of rAAVs (approx. 4.7 kb), the SpCas9 
cannot be packaged together with the corresponding sgRNA cassette and therefore needs to 
be delivered via two separate rAAVs. It has been shown that co-application of dual rAAVs into 
the retina results in sufficient transduction levels, which render its therapeutic implementation 
feasible (18, 22, 28, 29). Furthermore, to combat the potential risk of immune responses due 
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to the expression of the bacterial SpCas9 enzyme, strategies have been developed to ensure 
only a transient expression of this protein in the target cells (22). Moreover, it remains to be 
determined what percentage of wild type CLRN1 transcript is sufficient to achieve a therapeutic 
effect in the USH3A patients and/or animal models. It has been shown for other retinal and 
non-retinal autosomal-recessive disorders that already a few percent of the intact gene can 
achieve substantial functional and phenotypic rescue (30-32). Our gene editing efficiency 
ranges between approx. 30 % obtained via densitometric analysis and 64 – 84 % as calculated 
from the NGS data. The exact reason for this discrepancy between the methods remains 
unknown. But regardless of which of these values most closely reflects the true efficiency of 
gene editing, it may already be high enough to achieve therapeutic success in patients.  
We provide primary evidence that both, the CRISPR-Cas9 and the AON approach, do not 
cause off-targets under the conditions used herein further supporting the therapeutic potential 
of these strategies. Nevertheless, additional experiments are required to interrogate off-target 
effects in a broader and clinically more relevant setting using e.g. whole genome sequencing 
or similar quantitative approaches. A recent study reported no apparent off-targets for two 
sgRNAs in a CRISPR-Cas9-based approach for LCA treatment in the retina (22). This shifts 
the risk-benefit balance in favor of utilizing such gene editing technologies to treat conditions 
for which other alternatives are currently unavailable. 
One plausible strategy to increase the splice rescue efficiency and thus the chance of a 
successful treatment would be to combine both technologies in a single approach. Our results, 
however, suggest that AONs, which target similar positions close to the sgRNA target sites, 
reduce the SpCas9-mediated DNA cleavage efficiency. In line with other studies (33, 34), this 
indicates that AONs can also efficiently target genomic DNA and raises the question whether 
combining CRISPR-Cas9 and AONs is meaningful. This finding is particularly important as it 
provides a new research avenue for developing AON-based and target-specific SpCas9 
inhibitors. 
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This work evaluates the therapeutic potential of CRISPR-Cas9- and AON-based strategies to 
correct the splicing of the CLRN1 c.254-649T>G mutation, and offers initial premise for further 
preclinical development, which could lead to the first clinical trials for USH3A patients. 
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Materials and Methods 
Animals 
For all animal experiments in this study, wild type C57BL/6J mice were used. All procedures 
involving animals were performed with permission of the local authorities (District Government 
of Upper Bavaria) and German laws on animal welfare (Tierschutzgesetz). Anesthesia was 
performed by intraperitoneal injection of ketamine (40 mg/kg body weight) and xylazine (20 
mg/kg body weight). Euthanasia was performed by isoflurane and cervical dislocation. 
 
Construction and cloning of expression plasmids 
Minigenes suitable for splicing analysis were constructed and cloned as described 
previously (7, 35). The wild type (wt) and mutant (mut) CLRN1 minigenes were synthesized 
by BioCat (Heidelberg, Germany) and delivered in a pcDNA3.1 standard vector. These 
constructs were used for transient expression in HEK293 cells. For a stable expression in 
this cell line, the wt and mut minigene cassettes including the SV40 polyadenylation signal 
were subcloned into a piggybac vector (PB514B-2-SBI, BioCat, Heidelberg, Germany). For 
expression in mouse photoreceptors, the CLRN1 wt and mut minigenes were subcloned 
into the pAAV2.1 vector (36) equipped with a murine rhodopsin promoter. The SpCas9 
coding sequence and short synthetic polyadenylation signal was taken from the PX551 
plasmid (37) and subcloned into the pAAV2.1 plasmid containing a minimal CMV promoter.  
PX551 was a gift from Feng Zhang (Addgene plasmid #60957; 
http://n2t.net/addgene:60957; RRID: Addgene_60957). Due to the limited rAAV packaging 
capacity of approximately 4.7 kb, the different sgRNA sequences (Suppl. Table 2) driven by 
a U6 promoter were cloned into a separate pAAV2.1 plasmid. For FACS experiments, a 
T2A and EGFP sequence was added 3’ of the SpCas9 coding sequence and the sgRNA 
expression cassettes were cloned into the same expression vector. All constructs were 




Cell culture and transfection 
The ARPE-19 cell line was a gift from the LMU University Eye Hospital in Munich, Germany. 
The cells were cultivated in DMEM/F-12 (1:1) medium (GibcoTM, Thermo Fisher Scientific, 
Waltham, MA) containing L-Glutamine, 10 % FBS (Biochrom, Merck, Darmstadt, Germany) 
and 1 % penicillin/streptomycin (Biochrom, Merck) at 37 °C and 5 % CO2. The cells were 
transfected with a SpCas9- and sgRNAs-containing plasmid using the standard calcium 
phosphate transfection protocol. For this purpose, cells were seeded onto 6 cm cell culture 
plates and incubated overnight until they reached the desired confluence of approximately 70 
%. For the transfection, 6 µg of plasmid DNA (3 µg per plasmid) were mixed with 30 µl of 2.5 
M CaCl2 and 270 µl H2O. 600 µl 2x BBS were added dropwise during vortexing. The 
transfection mix was incubated for 3 – 4 minutes at room temperature and added dropwise to 
the culture medium. The cells were incubated in a 5 % CO2 setting for 3 – 4 h, the culture 
medium was replaced and the cells were maintained at 10 % CO2 for approximately 48 h. No 
transfection toxicity was detected. The murine 661W cell line derived from retinal tumors was 
kindly provided by Dr. Muayyad Al-Ubaidi, University of Houston (38). The cells were cultured 
in DMEM GlutaMAX medium (Thermo Fisher Scientific, Waltham, MA) supplemented with 10 
% FBS (Biochrom, Merck) and 1 % Anti-Anti (Thermo Fisher Scientific, Waltham, MA) at 37 
°C and 10 % CO2. Immortalized mouse embryonic fibroblasts (MEFs) were generated as 
previously described (39, 40). MEF cells were cultured in DMEM GlutaMAX medium 
supplemented with 10 % FBS (Biochrom, Merck) and 1 % penicillin/streptomycin (Biochrom, 
Merck) at 37 °C and 5 % CO2. Transient transfections of 661W and MEF cells were performed 
using the TurboFect transfection reagent (Invitrogen, Thermo Fisher Scientific, Waltham, MA) 
according to the manufacturer’s instructions. HEK293 cells were transfected with the 
respective minigenes and (if applicable) with a SpCas9/sgRNA-encoding plasmid using the 






48 h post-transfection, the cells were harvested and lysed using the mixer mill MM400 
(Retsch, Haan, Germany). RNA was isolated using the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instructions and RNA concentration purity was 
determined via the NanoDrop2000 (Thermo Scientific, Waltham, MA). cDNA was 
synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific , 
Waltham, MA) according the manufacturer’s instructions for 1 µg total RNA. For subsequent 
RT-PCR, the Herculase II fusion DNA polymerase (Agilent Technologies, Santa Clara, CA) 
was used according to the manufacturer’s instructions using appropriate primers designed 
to exclusively amplify the CLRN1 minigene-born transcript (Suppl. Table 3). The PCR 
products representing the differentially spliced transcripts were isolated using the QIAquick 
Gel Extraction kit (Qiagen, Venlo, Netherlands) and sequenced (Eurofins Genomics, 
Ebersberg, Germany). 
 
Isolation of genomic DNA and PCR 
Genomic DNA (gDNA) was isolated from transfected and untreated cells. The cells were 
lysed in RLT buffer (Qiagen, Venlo, Netherlands) containing 1 % β-mercaptoethanol (Sigma 
Aldrich, St. Louis, MO) using the mixer mill MM400 (Retsch, Haan, Germany). For gDNA 
isolation, the lysate was loaded onto a Zymo-Spin IIC-XL DNA column (Zymo Research, 
Irvine, CA). The column was subsequently washed once using 600 µl of the DNA Pre-Wash 
Buffer (Zymo Research, Irvine, CA) followed by two washing steps with 600 µl of the g-DNA 
Wash Buffer (Zymo Research, Irvine, CA). Genomic DNA was eluted in the appropriate 
volume of H2O containing 20 mM 2,6-di-tert-butyl-4-methylphenol. For subsequent PCR 
using the Q5 polymerase according to the manufacturer’s instructions, 100 ng of gDNA were 
used. All obtained PCR bands were isolated using the QIAquick Gel Extraction kit (Qiagen, 




Fluorescence-activated cell sorting 
HEK293 and ARPE-19 cells transfected with the SpCas9-T2A-EGFP construct were sorted via 
fluorescence-activated cell sorting (FACS) for nascent GFP. For this purpose, the cells were 
detached 48 h post-transfection using TryPLE. After detachment, the TryPLE was removed by 
centrifugation at 0.3 rcf for 5 min and aspirated. The cell pellet was resuspended in sample 
buffer (2 % FBS, 2 mM EDTA, 25 mM HEPES in PBS) and the suspension was stained with a 
viability dye (Sytox Blue, Thermo Fisher Scientific, Waltham, MA). Cell sorting was performed 
on a FACS Aria IIIu (Becton Dickinson, Franklin Lakes, NJ) equipped with the BD FACSDiva 
software v8.0. HEK293 and ARPE-19 cells were sorted with a 100 μm nozzle at 20 psi and 
with a 130 μm nozzle at 10 psi, respectively. Viable cells were gated from non-viable and from 
mock-transfected cells expressing the SpCas9 without any fluorophore. A range between 
100,000 – 250,000 cells were sorted. GFP-expressing cells were sorted into RLT buffer 
containing 1 % β-mercaptoethanol (Sigma Aldrich, St. Louis, MO) and used directly for gDNA 
extraction.  
 
Whole exome sequencing and off-target analysis 
1 µg of gDNA of native HEK293 and SpCas9-treated cells was fragmented to an average size 
of 150 bp using the Covaris M220 Focused-ultra sonicator (Covaris, Woburn, MA). After DNA 
repair with the NEBNext FFBE DNA repair mix (New England Biolabs Inc., MA) paired-end 
sequencing libraries were constructed using the SureSelectXT reagent kit (Agilent, Santa 
Clara, CA). End repair, adapter ligation, and PCR enrichment and was carried out according 
to the manufacturer’s instructions. Protein-coding sequences were captured using SureSelect 
Human All Exon V6 (Agilent, Santa Clara, CA) according to the manufacturer’s instructions. 
Exome libraries were sequenced paired-end on an Illumina Hiseq 1500 sequencer with a read 
length of 100 nucleotides to an average coverage of 50x. The reads were mapped to the 
human reference genome (hg19) with BWA-MEM (41) using default settings. Single-nucleotide 
polymorphisms and INDELs were analyzed following the GATK workflow to discover somatic 
short variants (SNVs + Indels) (42, 43). Within the workflow, Mutect2 from the GATK Analysis 
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Toolkit was used to obtain variants specific to SpCas9-treated cells. The obtained variants 
were filtered using FilterMutectCalls, resulting in 273 SNVs and 35 Indels passing the filter 
(FILTER: PASS). Off-target analysis of those variants was performed by calculating the 
minimum Levenshtein distances. The two guide RNAs [5’-AAATCTGGCAGGACCAATCTTGG 
and 5’-TTAATGTAGCACAAAGCTGTGGG] were aligned in a sliding window, starting 30 bp 
up- and downstream of each variant position and the alignment with the smallest Levenshtein 
distance was determined. An alignment was only taken into consideration if the PAM sequence 
(NGG) was present. For comparison, the approach was applied to 1,000 randomly selected 
genomic positions. 
 
mRNA pre-processing and sequencing 
For mRNA-seq library production, we ran a scaled-up version of the SMARTseq2 protocol (44). 
Briefly, from 100 ng of total RNA, mRNA was captured with a mix of 0.5 µl of 20 µM oligo dT 
primer and 0.5 µl of 20 mM dNTPs followed by heating to 72° C for 3 min and immediately 
putting it into an ice-water bath. Next, in a 10 µl reaction, double stranded cDNA was generated 
by adding 2 µl of 5x Superscript II first-strand buffer (Thermo Fisher Scientific, Waltham, MA), 
2 µl of 5 M Betaine, 0.6 µl of 100 mM MgCl2, 0.5 µl of 100 mM DTT, 0.4 µl of RNAsin (Promega, 
Madison, WI), 0.5 µl of 20 µM of template-switch oligo (20 µM) and 0.5 µl of SuperScript II 
reverse transcriptase (200 U/µl, Thermo Scientific, Waltham, MA) and incubating the solution 
for 90 min at 42° C, followed by 14 cycles (50° C for 2 min, 42° C for 2 min) and heat inactivation 
(70° C for 15 min). Pre-amplification was done by addition of 12.5 µl of 2x KAPA HiFi HotStart 
Ready mix, 0.25 µl of 10 µM IS PCR primers and 2.25 µl of nuclease-free water in a thermos 
protocol of 98° C for 3 min, 10 pre-amp cycles (98° C for 20 sec, 67° C for 15 sec, 72° C for 6 
min), followed by 5 min at 72° C and hold at 4° C. Purification was done with AMPure XP beads 
(Beckman Coulter, Brea, CA), cDNA was quantified with Qubit (Thermo Scientific, Waltham, 
MA) and checked for fragment length distribution on an Agilent Bioanalyzer chip (Agilent, 
Santa Clara, CA). Next, 7 ng of cDNA were fragmented in a 20 µl reaction by incubation with 
1 µl of Tn5 enzyme from the Illumina Nextera library preparation kit (Illumina, San Diego, CA) 
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and 10 µl of 2x tagmentation DNA buffer for 10 min at 55° C. Tagmented cDNA was purified 
with MinElute columns (Qiagen, Venlo, Netherlands) and PCR amplified with NEBNext High-
Fidelity 2x PCR  Mastermix, 1 µl of each 10 µM Nextera index 1 and  Nextera index 2 primer 
(Illumina, San Diego, CA) with a thermos protocol of 72° C for 5 min, 98° C for 30 sec, 7 cycles 
(98° C for 10 sec, 63° C for 30 sec, 72° C for 1 min), 72° C for 5 min and hold at 4° C. The final 
library was purified with AMPure beads, quantified by Qubit and sequenced for 100 basepairs 
using a V3 single read flow cell on a HiSeq 2500 (Illumina, San Diego, CA). The generated 
data was trimmed for quality and adapter reads with TrimGalore! 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and mapped with the STAR 
aligner (45). Duplicates were marked with the MarkDuplicates function from Picard tools 
(https://broadinstitute.github.io/picard/) and the reads were summarized with RSEM (46). 
 
AON off-target analysis 
In silico prediction for genomic binding sites was performed with gggenome online tool 
(https://gggenome.dbcls.jp/hg38/4/) using the AON sequence (5’- 
CUUUCAUCUGGUGAGGCAUCAGC -3’) to query the human genome (top and bottom strand 
and allowing up to 4 mismatches/gaps). Potential binding sites (n = 1150) were extended by 
10 kb up- and downstream and all annotated transcript isoforms overlapping these windows 
were flagged as potential AON off-targets. Among the most deregulated transcripts (TPM log2 
fold change > 1 or < -1) we found no enrichment for potential AON off-target transcripts by 
using a Fisher’s exact test. 
 
Targeted NGS and data processing 
The 100 ng of the DNA isolated from FAC-sorted HEK293 and ARPE-19 cells were amplified 
using the Q5 polymerase (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions (35 cycles) with appropriate primers (Suppl. Table 3). The PCR 
products were co-purified using the QIAquick Gel Extraction kit (Qiagen, Venlo, 
Netherlands). Purified amplicons from each sample were tagged with a unique NGS 
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barcode by PCR (7 cycles) followed by a final clean-up (Agencourt AMPure XP Beads, 
Beckman Coulter, Brea, CA). Finally, all samples (set to 10 nM) were pooled, loaded on an 
Illumina MiSeq sequencing machine (Illumina, San Diego, CA) and sequenced for 2x 250 
bp paired-end with a MiSeq reagent kit V3 (Illumina, San Diego, CA) to approx. 200k fold 
coverage. The raw data was quality checked using FastQC and trimmed for adaptors or 
low-quality bases using the tools cutadapt and Trim Galore! 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Next, reads were sorted 
in a two-step procedure by (i) the NGS barcode adaptors to assign the reads and (ii) the 
first and the last 20 bp of each read to assign an amplicon ID. Obtained reads were then 
counted depending on the presence of either the original wild type sequence (at both sgRNA 
cutting sites plus/minus 15 bp) or the presence of a new fusion omitting a 187 bp fragment 
between the two sgRNA binding sites (see Suppl. Fig. 4). 
 
Generation and delivery of antisense oligonucleotides 
The sequence of the aberrant CLRN1 exon was screened for exonic splicing enhancer 
(ESE) sequences using the ESEfinder 3.0 (http://krainer01.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home). AONs were designed to either cover multiple 
SRSF1, SRSF2, SRSF5 and SRSF6 motifs, the donor splice site or intronic splice enhancer 
motifs present in the intronic sequence adjacent to the novel donor splice site (Suppl. Table 
1). All AON sequences contain 2’-O-methyl modified riboses and a phosphorothioate 
backbone and were synthesized by Eurofins Genomics (Ebersberg, Germany). For splicing 
rescue in transfected HEK293, 661W or MEF cells and in HEK293 stable cell lines, AONs 
were added to the cell medium at a final concentration of 250 nM (1.2 – 8 µg depending on 
the growth medium volume) unless stated otherwise. For in vivo experiments, AONs were 




Generation of stable cell lines 
The stable cell lines were generated using the piggybac transposon system. Briefly, 
HEK293 cells were co-transfected with the respective CLRN1 minigene containing piggybac 
vector and a piggybac transposase expression vector using a standard calcium phosphate 
transfection protocol. 24 h post-transfection, cells were selected for successful integration 
of the piggybac expression cassette by adding 2 µg/ml puromycin to the media for 8 days. 
The presence of RFP fluorescence indicating successful integration was confirmed using 
the EVOS® FL cell imaging system (Life Technologies, Thermo Fisher Scientific, Waltham, 
MA). 
 
rAAV production  
For the production of recombinant adeno-associated viral (rAAV) vectors, the 7M8 capsid (47, 
48) was used for SpCas9 and sgRNA expression in human retinal pigment epithelial (hRPE) 
cells. For the expression of human CLRN1 minigenes in the mouse retina, the 2/8YF capsid 
variant was used (49). rAAVs were produced as described previously (28, 50).  
 
Human retinal pigment epithelium cell culture and transduction 
The hRPE cells were a gift from the LMU University Eye Hospital in Munich, Germany. The 
cells were cultivated in DMEM GlutaMAX high glucose (4.5 g/l) medium (GibcoTM, Thermo 
Fisher Scientific, Waltham, MA) containing 10 % FBS (Biochrom, Merck, Darmstadt, Germany) 
and 1 % penicillin/streptomycin (Biochrom, Merck, Darmstadt, Germany) at 37 °C and 5 % 
CO2. The cells were transduced with 7M8 rAAVs with a multiplicity of infection (MOI) of 
100,000. The medium was replaced after 48 h and cells were harvested 7 days post-
transduction. 
 
Subretinal injections and RT-PCR 
1 µl containing 1010 viral particles and 27.6 µg of AON2.2 were delivered subretinally via a 
single injection into six-month old C57Bl/6J wildtype mice. Correct subretinal application 
was confirmed by transient retinal detachment during the injection. Four weeks post -
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injection, the retinas were harvested and further processed for RNA isolat ion. Two retinas 
were pooled per construct. RNA isolation and cDNA synthesis were performed as described 
above. For cDNA synthesis, 1 µg total RNA was used. For RT-PCR, the Q5 polymerase (New 
England Biolabs, Ipswich, MA) was used according to the manufacturer’s instructions and 
minigene-specific primers were used to avoid amplification of endogenous Clrn1. 
 
Quantitative RT-PCR 
qRT-PCR was performed on the StepOnePlus Real-Time PCR System (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA) using the SYBR Select Master Mix (Applied 
Biosystems, Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s 
instructions. The expression of CLRN1 was normalized to the housekeeping gene beta actin 
(ACTB) to obtain the ΔCT value. A higher ΔCT value reflects a lower gene expression with 
respect to ACTB. For quantification of the different CLRN1 minigene-born splice isoforms, the 
expression was normalized to ACTB and to the overall expression of the transfected plasmid 
to avoid artefacts due to potential differences in the transfection efficiency. 
 
Statistics 
All values are given as mean ± SEM. The number of replicates (n) and the used statistical tests 
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Suppl. Fig. 1 Sequencing of the edited CLRN1 locus and the CLRN1 transcript. A, PCR 
amplifying the genomic endogenous wild type CLRN1 locus originating from HEK293 cells 
expressing the SpCas9 with the g1 + g3 combination. untrd, untreated. B, Sequencing results 
of the bands depicted in A. The grey box represents the aberrant exon. The excision induced 
by the catalytic activity of the SpCas9 is indicated with a dashed red line. C, Transiently 
transfected HEK293 cells sorted for nascent GFP fluorescence. Cells transfected with a 
SpCas9 construct without a fluorophore were used as a mock control (lower panel). SCA, 
single channel analyzer. D, RT-PCR from HEK293 cells transiently expressing wild type (wt) 
or mutant (mut) CLRN1 minigenes or the mutant minigene in combination with A2. E, Scheme 
depicting the single splicing events (highlighted in different colors) occurring between exon 0b 
and exon 1 of the CLRN1 pre-mRNA as detected in D. F, Sequencing results of the different 
CLRN1 transcript variants shown in D. Band number 7 represents a hybrid band consisting of 






Suppl. Fig. 2 A, qRT-PCR from HEK293 cells transiently transfected with the single CLRN1 
minigenes in presence or absence of A2.2 as indicated. Each lane contains two data sets 
originating from the primer combinations amplifying the aberrantly spliced CLRN1 (0b-ae) or 
both correctly and aberrantly spliced CLRN1 (0b-1) as depicted in the lower panel. The 0b-
ae/0b-1 ratio for the single combinations is shown above the corresponding relative expression 
values. B, Representative RT-PCR showing splicing correction efficiency in relation to different 
A2.2 concentrations. The corresponding quantification based on the densitometric PCR band 
analysis is shown below. Statistical analysis was done with one-way ANOVA followed by a 
Benferroni’s post-hoc test. n.s., not siginificant. C-D, Representative RT-PCR from MEF (C) or 
661W cells (D) including the densitometric quantification for the single transfections as 
indicated. Statistical analysis was conducted using the unpaired t-test. ***, p ≤ 0.001. E-F, 
RNA-seq scatter plots from HEK293 cells transfected with the mutant CLRN1 minigene in 
presence (x-axis) or absence (y-axis) of A2.2. Red dots in the scatter plots illustrate the 
potential off-target transcripts (n = 1978, details see Methods). Expression of the four 
annotated CLRN1 transcripts as highlighted. TPM, transcripts per kilobase million. F, MA-plot: 
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The red line indicates the overall reduction of gene expression in the mut + A2.2 sample as 
compared to the dashed blue line. 
 
Suppl. Fig. 3 FAC-sorting of ARPE-19 cells and sequencing of edited CLRN1 locus in 
ARPE-19 and hRPE cells. A, Transiently transfected ARPE-19 cells sorted for nascent GFP 
fluorescence. Cells transfected with a SpCas9/sgRNA construct without a fluorophore were 
used as a mock control (right panel). SCA, single channel analyzer. B, PCR from genomic 
DNA isolated form transiently transfected and FAC-sorted APRE-19 cells. untrd, untreated. C, 
Sequencing results of the bands depicted in B. The grey box represents the aberrant exon. 
The excision induced by catalytic activity of the SpCas9 is indicated with a dashed red line. D, 
PCR from genomic DNA isolated from transduced hRPE cells one week post-infection. E, 




Suppl. Fig. 4. Quantification and off-target effects of the gene editing using NGS. A, Co-
purified PCR amplicons from sorted HEK293 and ARPE-19 cells used for targeted NGS. B, 
Sequence of the PCR amplicon and strategy for quantification. Red letters indicate the region 
which will be removed from the CLRN1 locus upon SpCas9 cleavage in presence of g1 + g3. 
Due to the sequencing length (up to 250 bp from both molecule ends), the uncut or cut 
sequence (571 bp vs. 388 bp) could not be identified as one single entity for quantification. 
The strategy for detecting these products is based on the characteristic sequences present in 
the cut or uncut products as highlighted by the different colors and as explained in the text 
below the sequence. C, Quantification of the reads for the single bands and cell types as 
indicated. D, List of most frequent CLRN1 sequences identified using targeted NGS. The cut-
off value was set to 0.35 %. The uncut and cut CLRN1 sequences are listed on top for 
reference. Read 1 (left panel) and read 2 (right panel) covered the target sequence of sgRNA 
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g1 and g3, respectively. freq, frequency.  E, Levenshtein distances of sgRNAs around 
identified variants. The histogram in orange shows the number of minimal Levenshtein 
distances from the alignments of the two sgRNAs (g1 and g3) to all variants specific to SpCas9 
treated HEK293 cells within a sliding window 30 bp up- and downstream of the variant position. 
The blue histogram shows the minimal distances from 1,000 randomly chosen genomic 
positions. At least seven base modifications (exchange, deletion, insertion) would be required 
around the candidate regions of each variant to match one of the two sgRNAs. This indicates 
that these variants do not represent off-target effects. F, IGV browser plots of untreated and 
treated HEK293 cells in the CLRN1 locus.  Forward and reverse mapped reads were colored 
pink and blue, respectively. The targets of the two sgRNAs (g1 and g3) are highlighted as blue 




Suppl. Table 1 Sequences of antisense oligonucleotides and masked splicing elements 
AON Sequence Masking of 
A1 5’ GGACAAGAUUCCUGUUGUCUC 3’ 
SRSF1, SRSF2, SRSF5 & SRSF6 
motifs 
A2 5’ UUCAUCUGGUGAGGCAUCAG 3’ SRSF1, SRSF5 & SRSF6 motifs 
A3 5’ CGAAACCCUACCUUUUAGGG 3’ 
SRSF1 motif & novel donor splice 
site 
A4 5’ UUUUAGGGCUUCUUUCAUCU 3’ Novel donor splice site 
A5 5’ UGCAGAGAAAGCGAAACCCU 3’ ISE motif group A (51) 
A2.1 5‘ UUCAUCUGGUGAGGCAUC 3‘ SRSF1, SRSF5 & SRSF6 motifs 
A2.2 5‘ CUUUCAUCUGGUGAGGCAUCAGC 3‘ SRSF1, SRSF5 & SRSF6 motifs 
A2.3 5‘ CUGGUGAGGCAUCAGCAUGC 3‘ SRSF1, SRSF5 & SRSF6 motifs 
 
Suppl. Table 2 sgRNA targeting sequences. The corresponding PAM sequences are shown 
in italic.  
sgRNA targeting sequences 
CLRN1 g1 5’ AAATCTGGCAGGACCAATCT TGG 3’ 
CLRN1 g2 5’ TGGTGAGGCATCAGCATGCT TGG 3’ 
CLRN1 g3 5’ TTAATGTAGCACAAAGCTGT GGG 3’ 
CLRN1 g4 5’ TCTACACCAAGATTAAAGAA TGG 3’ 
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Suppl. Table 3 Primers used in this study. 
Primer name Sequence 5’ – 3’ 
CLRN1 exon0b forward TTGACCCCTTCATGGGACTC 
CLRN1 exon1b reverse TTGAGCCTGGTGCCTGGTA 
pcDNA3.1 forward ACTATAGGGAGACCCAAGCTG 
piggybac forward CCATCCACGCTGTTTTGACC 
CLRN1 genomic intron forward GGTTATAAGCTCTGTGAGACAAC 
CLRN1 genomic intron reverse CCAAGCCTTTAATGACCTTTCTCG 
qPCR CLRN1 exon 1 forward CATGGTCCCCTAGGGCTGTACC 
qPCR CLRN1 exon 1b reverse GCCTGGTAGCTGGCAGCCAAA 
qPCR CLRN1 exon 0b-ae or 0b-1 forward AAACTCCATGCAGGCCCTGC 
qPCR CLRN1 exon 0b-ae reverse CAGGACCAATCTGGGGAAGTT 
qPCR CLRN1 exon 0b-1 reverse GGCTGTCCCCACCATGGTTA 
qPCR CLRN1 plasmid forward TTGCCCTTTGGCTGCCAGC 
qPCR CLRN1 plasmid reverse GGTGGCGACCGGTAGATCTAT 
CLRN1 NGS forward 
TCTTTCCCTACACGACGCTCTTCCGATCTG
GTTATAAGCTCTGTGAGACAAC 
CLRN1 NGS reverse 
GTGACTGGAGTTCAGACGTGTGCTCTTCC
GATCTCCAAGCCTTTAATGACCTTTCTCG 




I have tested two promising therapeutic approaches to pave the way for the more advanced 
pre-clinical trial to treat USH3A patients carrying the deep intronic c.254-
649T>G CLRN1 splicing mutation. In this context, I evaluated the potential of CRISPR-Cas9 
and antisense-oligonucleotide-based gene editing, two technologies working at the DNA or 
pre-mRNA level, respectively [103]. Both approaches were tested in different human and 
murine cells lines, and yielded reasonable splice rescue efficiency. Moreover, AONs could 
rescue the mRNA splicing to a considerable extent in the mouse retina. Walmsley et al. used 
AONs for the treatment of the muscular phenotype in Cavalier King Charles Spaniels, carrying 
a naturally occuring mutation in the Duchenne muscular dystrophy (DMD) gene [104]. This 
missense mutation leads to a frameshift resulting in a truncated protein [104]. By the help of 
AON-based gene editing, they were able to restore the reading frame in myoblasts obtained 
from affected dogs. In another study, Amoasii et al. could restore the reading frame in another 
dog model for Duchenne muscular dystrophy (DMD), using the CRISPR-Cas9 technology 
[105]. Moreover, a recently published work showed a morphological and functional 
improvement in a pig model for DMD treated with Cas9 designed to cut out the exon harboring 
the mutation and resulted in a restoration of the reading frame [106]. AONs have been utilized 
in the past for the treatment of splicing mutations for LCA, Usher syndrome type II (USH2) or 
Stargardt disease [54], [107], [108]. These findings let to first clinical trials using AONs for 
patients carrying the most common deep-intronic c.2991+1655A>G mutation in CEP290 gene 
[109], [110]. These findings outline the great potential of AON and CRISPR-Cas9-based 
technologies for future therapies. An advantage of AONs is their easy way of application as 
naked molecules and the high efficiency to be taken up by the different retinal cell types. 
Another important advantage of AONs is their relatively cost-friendly production in contrast to 
recombinant adeno-associated viruses (rAAVs), whose production is costly and time-
consuming. However, AON administration must be applied continuously in intervals of a few 
months in contrast of CRISPR-Cas9 approach, where a single administration is sufficient.  
Such frequent administration enhances the risk of adverse effects and collateral damage for 
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the patients. Using the minimal cytomegalovirus (CMV) vector, Cas9 can be efficiently 
expressed in all retinal cell types [93]. However, also this technology has it´s limiting factors, 
e.g. the large size of the different Cas9 modules, which (depending on the Cas type and vector 
design) can violate the DNA packaging capacity of AAV vectors. This means that SpCas9 and 
sgRNA cassette typically need to be delivered via two separate rAAVs (dual AAV vectors). 
Dual AAV vectors, however further increase the costs and time investment for the production. 
In addition, dual AAVs require high co-transduction efficiency in the target cells. Nevertheless, 
studies have shown that the application of two rAAVs resulted in high levels of co-transduction 
[93], [111]–[113]. Furthermore, due to its bacterial origin, SpCas9 increases the risk of immune 
responses in the target cells or tissues. However, several strategies have been provided in 
previous studies designed to ensure a transient expression of Cas9 [93] [114]. Finally, both 
CRISPR-Cas9 gene editing and AONs can induce off-target effects at the genome or 
transcriptome level, respectively. Whole exome sequencing (WES) and RNA sequencing 
(RNAseq) could exclude off-targets under the conditions used herein. Likewise, a recent 
published study reported about no apparent off-targets for a CRISPR-Cas9 based approach 
for LCA treatment in the retina [93]. However, it cannot be excluded that some off-targets could 
be detectable in a more native setting. In this study, I also show that there are no synergistic 
effects when combining AONs and CRISPR-Cas9 in a single approach. One plausible 
explanation could be that AONs bind to the target sequence at the genome and prevent the 
Cas9 complex from binding and/or cutting the DNA. Nevertheless, further experiments are 
required to evaluate this hypothesis, which could lead to the development of novel specific 
SpCas9 inhibitors. Taken together, I show that the CRISPR-Cas9 as well as the AON approach 
provide a significant splice rescue for the deep intronic c.254-649T>G CLRN1 splicing mutation 
with no apparent off-target effects. These promising results require further preclinical 
development that might result in first clinical trials of USH3A patients. The results shown here 
can be transferred to veterinary medicine and thus become important for the treatment of 
exonic or intronic splicing mutations like PRAs, CRDs or CSNB. Even though both approaches 
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bear some disadvantages and risks. The absence of alternatives to treat genetic disorders 
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